LONDON (Alliance News) - Nutrition products group Provexis PLC said Monday that results from the first stage of its collaboration deal with the University of Oslo are "very encouraging."
The company has a collaboration deal with the university to research further into the relationship between its food ingredient Fruitflow and blood pressure regulation. Key results from the first stage of works show "strong evidence" that a standard 150 gram dose of Fruitflow in powder format has "the potential to give a clinically relevant reduction in systolic blood pressure."
The second stage of work will involve a small clinical trial, and study designs are currently being prepared for ethics approval.
"The collaboration is an important step in maximising the opportunities available to commercialise Fruitflow, and we look forward to continuing the development of this very promising blood pressure lowering programme," said Chairman Dawson Buck in a statement.
Shares in Provexis are trading up 8.3% at 0.633 pence Monday morning, one of the best performers in the AIM All-Share.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Provexis (PXS)